We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$580M
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
-22.55%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$194M
AUM Growth
+$14.4M
(+8%)
Cap. Flow
+$69.7M
Cap. Flow
% of AUM
35.98%
Top 10 Holdings %
Top 10 Hldgs %
60.4%
Holding
41
New
9
Increased
19
Reduced
7
Closed
6
Avg Time Held Equity + Options
1.7
quarters
Top 10 Avg Time Held Equity + Options
0.9
quarters
Top 20 Avg Time Held Equity + Options
1.8
quarters
Avg Time Held Equity only
1.7
quarters
Top 10 Avg Time Held Equity only
0.9
quarters
Top 20 Avg Time Held Equity only
1.8
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$13.4M |
| 2 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$10.6M |
| 3 |
Cigna
CI
|
+$9.19M |
| 4 |
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$6.37M |
| 5 |
Everforth Inc
EFOR
|
+$5.72M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Palvella Therapeutics
PVLA
|
+$5.15M |
| 2 |
MacroGenics
MGNX
|
+$4.42M |
| 3 |
SHPG
Shire pic
SHPG
|
+$4.24M |
| 4 |
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
|
+$4.1M |
| 5 |
Indaptus Therapeutics
INDP
|
+$4.02M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.94% |
| 2 | Technology | 2.47% |
| 3 | Financials | 0.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
HNGR
1
DELISTED
Hanger Inc.
HNGR
| $22.5M | 11.64% |
1,189,399
-10,203
| -0.9% | -$197K |
2018 Q3
1 quarter
|
|
|
RETA
2
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $14.2M | 7.33% |
253,000
+172,845
| +216% | +$10.6M |
2017 Q4
4 quarters
|
|
|
3
Cigna
CI
$74.7B
| $13.9M | 7.19% |
73,300
+44,064
| +151% | +$9.19M |
2018 Q1
3 quarters
|
|
|
WCG
4
DELISTED
Wellcare Health Plans, Inc.
WCG
| $11.8M | 6.09% |
+50,000
| New | +$13.4M |
2018 Q4
0 quarters
|
|
|
ARNA
5
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $10.8M | 5.58% |
277,650
+33,600
| +14% | +$1.32M |
2018 Q1
3 quarters
|
|
6
Zimmer Biomet
ZBH
$17.6B
| $10.7M | 5.54% |
106,481
+40,633
| +62% | +$4.57M |
2018 Q3
1 quarter
|
|
7
Iovance Biotherapeutics
IOVA
$6.57B
| $9.4M | 4.85% |
1,062,500
+347,183
| +49% | +$3.35M |
2017 Q4
4 quarters
|
|
8
BioMarin Pharmaceuticals
BMRN
$10.5B
| $8.77M | 4.53% |
103,000
+6,572
| +7% | +$625K |
2018 Q1
3 quarters
|
|
|
AGN
9
DELISTED
Allergan plc
AGN
| $8.21M | 4.24% |
61,400
+30,000
| +96% | +$4.92M |
2017 Q4
4 quarters
|
|
|
ALBO
10
DELISTED
Albireo Pharma Inc
ALBO
| $6.63M | 3.42% |
270,146
+107,241
| +66% | +$2.83M |
2018 Q3
1 quarter
|
|
11
Assembly Biosciences
ASMB
$414M
| $6.24M | 3.22% |
22,995
+13,030
| +131% | +$3.77M |
2018 Q2
2 quarters
|
|
|
12
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
| $5.77M | 2.98% |
+62,850
| New | +$6.37M |
2018 Q4
0 quarters
|
|
|
13
Indaptus Therapeutics
INDP
$318M
| $5.1M | 2.63% |
302
-295
| -49% | -$4.02M |
2018 Q2
2 quarters
|
|
|
TLGT
14
DELISTED
Teligent, Inc
TLGT
| $4.86M | 2.51% |
354,761
+30,685
| +9% | +$802K |
2018 Q1
3 quarters
|
|
|
15
Everforth Inc
EFOR
$1.57B
| $4.78M | 2.47% |
+87,700
| New | +$5.72M |
2018 Q4
0 quarters
|
|
16
Viking Therapeutics
VKTX
$3.39B
| $4.77M | 2.46% |
624,000
+349,590
| +127% | +$4.18M |
2018 Q3
1 quarter
|
|
17
DELISTED
ModivCare
MODV
| $4.7M | 2.43% |
78,298
-6,919
| -8% | -$458K |
2018 Q3
1 quarter
|
|
18
Kura Oncology
KURA
$874M
| $4.45M | 2.29% |
316,581
+62,950
| +25% | +$834K |
2018 Q2
2 quarters
|
|
19
Axogen
AXGN
$2.12B
| $4.27M | 2.21% |
209,088
+132,347
| +172% | +$4.14M |
2018 Q3
1 quarter
|
|
|
SBBP
20
DELISTED
Strongbridge Biopharma plc.
SBBP
| $4.2M | 2.17% |
937,900
+514,054
| +121% | +$2.51M |
2018 Q3
1 quarter
|
|
21
Gyre Therapeutics
GYRE
$711M
| $3.68M | 1.9% |
62,253
+30,712
| +97% | +$2.26M |
2018 Q3
1 quarter
|
|
|
SRRA
22
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $3.37M | 1.74% |
63,849
-4,153
| -6% | -$265K |
2018 Q1
3 quarters
|
|
23
Aldeyra Therapeutics
ALDX
$54.3M
| $3.36M | 1.73% |
+404,463
| New | +$4.14M |
2018 Q4
0 quarters
|
|
24
Centene
CNC
$34B
| $2.88M | 1.49% |
50,000
+10,250
| +26% | +$686K |
2017 Q4
4 quarters
|
|
|
25
MacroGenics
MGNX
$218M
| $2.46M | 1.27% |
194,129
-263,346
| -58% | -$4.42M |
2017 Q4
4 quarters
|
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q4 2018 Portfolio in Review
As of Q4 2018, Prosight Management held 41 positions worth $194M, up 8% from $179M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Prosight Management deployed $69.7M of net new capital in Q4 2018, opening 9 new positions and adding to 19 existing holdings. Its largest new stake was Wellcare Health Plans, Inc.: 50,000 shares worth $11.8M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Palvella Therapeutics, an estimated $5.15M trimmed.
- Prosight Management's largest Q4 2018 buy was Wellcare Health Plans, Inc.: 50,000 shares worth $11.8M.
- Prosight Management added most to Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2018, an estimated $10.6M increase.
- Prosight Management's biggest Q4 2018 reduction was Palvella Therapeutics, cutting an estimated $5.15M.
- Prosight Management fully exited Shire pic in Q4 2018, selling an estimated $4.24M.
- Prosight Management's ten largest holdings make up 60% of its $194M portfolio in Q4 2018.
- Prosight Management opened 9 new positions and closed 6 in Q4 2018.
- Prosight Management's portfolio value rose 8% quarter-over-quarter to $194M.
Based on Prosight Management's 13F filing for Q4 2018, filed 14 Feb 2019.